{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336844","form_type":"8-K","ticker":"VIVS","cik":"0001497253","company_name":"VivoSim Labs, INC.","filed_at":"2026-08-06T12:05:23+00:00","discovered_at":"2026-08-06T12:10:00.478232+00:00","generated_at":"2026-08-06T12:10:28.798924+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027","bullets":["Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.","Cash on hand as of Aug 3, 2026: ~$10.1M, reflecting recent inflows.","Reiterates FY2027 guidance of 500%+ revenue growth from NAMs contract research services.","Share count rose from 3.2M (June 30) to 13.4M (Aug 3) on warrant exercises.","Received $5M milestone from Eli Lilly, $1M escrow release, and $4M gross proceeds financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336844","json":"https://secwatch.observer/filing/0001193125-26-336844.json","markdown":"https://secwatch.observer/filing/0001193125-26-336844.md","text":"https://secwatch.observer/filing/0001193125-26-336844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/0001193125-26-336844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/vivs-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:10:28.798924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}